Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 6Cisplatin 6Nivolumab 5Gemcitabine 5Drug Therapy 5Radiotherapy 4Docetaxel 4pembrolizumab 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Endostatins 3Carboplatin 3tislelizumab 2endostar protein 2durvalumab 2camrelizumab 2Thalidomide 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Gefitinib 2Erlotinib Hydrochloride 2Bevacizumab 2Afatinib 2trilaciclib 1toripalimab 1titanium silicide 1osimertinib 1olaparib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Non-Small-Cell Lung × Heart Rate × Clear all
NCT06760676 2025-01-07

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Anhui Provincial Hospital

Phase 1 Not yet recruiting
90 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡